I am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter @theroberthart or email me at [email protected]
AstraZeneca’s injectable antibody therapy is effective at preventing severe illness or death in people with mild or moderate Covid-19 infections, the British pharmaceutical company
Monday, buoying confidence as scientists race to develop tools to treat coronavirus patients outside of hospital settings. AstraZeneca said its antibody therapy, AZD7442, halved the risk of developing severe Covid-19 or death compared to an inactive placebo in some 822 patients taking part in the late-stage clinical trial.
The patients—most of whom were at high risk of severe illness and had other diseases—received the antibodies within a week of showing symptoms. A separate analysis found the therapy to cut the risk of death or severe illness by two-thirds if given within five days of showing symptoms, AstraZeneca said.
AstraZeneca said it plans to discuss the data, which it did not disclose, with health authorities and plans to submit the trial’s full findings for publication in a peer-reviewed medical journal.it to be effective at preventing severe disease in high-risk individuals before exposure to the virus.The vast majority of Covid-19 treatments are geared towards patients already hospitalized with the disease and most of these treat the body’s response to the virus.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
AstraZeneca’s Injectable Antibody Cocktail Halves Risk Of Death Or Developing Severe Covid, Trial FindsI am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Lire la suite »
Covid-19: Three more Covid-related deaths and 1,115 new casesThe total number of coronavirus-linked deaths in NI since the start of the pandemic is 2,588.
Lire la suite »
Heart risks rare after Pfizer Covid vaccination, study findsHeart risks rare after Pfizer Covid vaccination, study finds; researchers identified 54 cases of myocarditis among more than 2,500,000 people ages 16 years and older who got at least one dose of the Pfizer vaccine
Lire la suite »
CDC: Norway, Bulgaria Now ‘Very High Risk’ For Travel Due To Covid-19CDC also raised the risk level for three other destinations. Singapore and Slovakia went from Level 2 to 3. And Equatorial Guinea jumped up to 3 from Level 1.
Lire la suite »
Covid-19: NHS Covid passes, and lockdown lifted in SydneyFive things you need to know about the coronavirus pandemic this Monday morning.
Lire la suite »